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Abstract
A continuous assay using internally quenched fluorescent peptides
with the general sequence Abz-peptidyl-(Dnp)P-OH (Abz = ortho-
aminobenzoic acid; Dnp = 2,4-dinitrophenyl) was optimized for the
measurement of angiotensin I-converting enzyme (ACE) in human
plasma and rat tissues. Abz-FRK(Dnp)P-OH, which was cleaved at
the Arg-Lys bond by ACE, was used for the enzyme evaluation in
human plasma. Enzymatic activity was monitored by continuous
recording of the fluorescence (λex = 320 nm and λem = 420 nm) at 37oC,
in 0.1 M Tris-HCl buffer, pH 7.0, with 50 mM NaCl and 10 µM ZnCl2.
The assays can be performed directly in the cuvette of the fluorimeter
and the hydrolysis followed for 5 to 10 min. ACE measurements in the
plasma of 80 healthy patients with Hip-His-Leu and with Abz-
FRK(Dnp)P-OH correlated closely (r = 0.90, P < 0.001). The specific-
ity of the assay was demonstrated by the complete inhibition of
hydrolysis by 0.5 µM lisinopril or captopril. Abz-FRK(Dnp)P-OH
cleavage by ACE was monitored in rat lung, kidney, heart, and liver
homogenates in the presence of a cocktail of inhibitors containing
trans-epoxy-succinyl-L-leucylamido-(4-guanido)-butene, pepstatin,
phenyl-methylsulfonyl fluoride, N-tosyl-L-phenylalanyl-chloromethyl
ketone, and N-tosyl-lysyl-chloromethyl ketone to prevent undesirable
hydrolysis. ACE activity in lung, heart and kidney homogenates, but
not in liver homogenates, was completely abolished by 0.5 µM
lisinopril or captopril. The advantages of the method are the proce-
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EC 3.4.15.1) is a dipeptidyl carboxypepti-
dase whose best-known physiological func-
tion is to cleave the C-terminal dipeptide of
angiotensin I to produce the potent vasocon-
strictor angiotensin II (1). ACE also inacti-
vates the vasodilator peptide bradykinin by
the sequential removal of two C-terminal
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dipeptides (2). ACE is expressed as a so-
matic isoform (150-180 kDa) in endothelial,
epithelial and neuroepithelial cells and as a
smaller isoform (90-110 kDa) only in germi-
nal cells in the testes. Somatic ACE is an
ectoenzyme attached to the cell membrane
composed of two highly homologous do-
mains, N- and C-domains, each possessing a
functional active site (3,4). The germinal
form of ACE is also a membrane-bound
enzyme which contains a single active site
corresponding to the C-domain of the so-
matic form (5,6). Plasma or soluble ACE is
derived from proteolytic shedding from the
cell membrane (7,8).
ACE is found in the plasma membrane of
vascular endothelial cells, with high levels
being present in the lung vascular endotheli-
al surface but the enzyme can be also found
in the epithelial cells of renal proximal tu-
bules, in the gastrointestinal tract, in cardiac
tissues, and in various regions of the brain
(9,10). This wide distribution of the enzyme
and its presence in many tissues where other
components of the renin-angiotensin system
are not present reinforce the idea that ACE
probably has other roles in addition to the
production of angiotensin II or the inactiva-
tion of bradykinin (11,12).
The hydrolysis of synthetic substrates
used for assaying ACE activity is detected
by spectrophotometric (13,14), fluorometric
(15-18), HPLC (19), radiometric (20), and
radioimmunoassay (21) methods. However,
each of these techniques has its own limita-
tions, such as being very laborious, having
low sensitivity, or employing substrates
whose products resulting from ACE activity
are destroyed by other enzymes, with a con-
sequent underestimate of ACE levels. There-
fore, convenient and specific substrates are
still required for the determination of ACE
activity in biological fluids and tissues.
We have described internally quenched
fluorogenic substrates for ACE with blocked
(Abz-peptidyl-EDDnp analogues of brady-
kinin where Abz is ortho-amino benzoic
acid and EDDnp is 2,4-dinitrophenyl ethyl-
enediamine) or free (Abz-peptidyl-K(Dnp)P-
OH) C-terminal carboxyl groups (22,23). In
the present study, we describe the suscepti-
bility of Abz-peptidyl-K(Dnp)P-OH deriva-
tives to hydrolysis by ACE from purified
rabbit lung. We also describe the use of these
substrates for ACE activity determinations
in human plasma and in crude extracts of rat
tissues. These internally quenched fluoro-
genic substrates provide a very sensitive
method for ACE determinations and can be
used on a continuous basis even at low ACE
concentrations. In addition, since the fluo-
rescence signal appears immediately after
hydrolysis, subsequent digestion of the prod-
ucts of ACE activity will not interfere with





64), phenyl-methylsulfonyl fluoride (PMSF),
pepstatin, N-tosyl-L-phenylalanyl-chloro-
methyl ketone (TPCK), N-tosyl-lysyl-chlo-
romethyl ketone (TLCK), and ortho-phthal-
dialdehyde were from Sigma (St. Louis, MO,




His-Leu were synthesized as described
(24,25). The internally quenched fluorogen-
ic peptides containing the Dnp group incor-
porated into the ε-NH2 of a Lys residue were
synthesized by the solid-phase methodol-
ogy, using Fmoc technology and H-Pro-2-
chlorotrityl resin (26). All the peptides ob-
tained were purified by semi-preparative
HPLC, and the molecular weight and purity
were checked by amino acid analysis and by
molecular mass determination with MALDI-
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TOF mass spectrometry, using a TofSpec E
from Micromass (Manchester, UK). Stock
solutions of the fluorogenic peptides were
prepared in DMSO and the concentrations
were determined using the EDDnp molar
extinction coefficient ε365 = 17,300 M-1 cm-1.
Enzymes
Purified rabbit lung ACE was purchased
from Sigma. The molar concentration of the
enzyme was determined by active site titra-
tion with lisinopril as described (27).
Human plasma samples
Blood was obtained from healthy donors
by arm venipuncture. All subjects gave writ-
ten informed consent to participate in the
study. The protocol was approved by the
Ethics Committee on Human Experimenta-
tion (Hospital São Paulo, Universidade Fe-
deral de São Paulo, São Paulo, SP, Brazil).
For the study, heparin-treated blood was
centrifuged at 1000 g for 10 min and plasma
was removed and stored at -20ºC.
Crude aqueous extracts of rat tissues
Samples of Wistar rat (200-250 g) lung,
kidney, heart, and liver were quickly har-
vested, rinsed, blotted, and homogenized in
Tris-HCl buffer, pH 7.0, containing 50 mM
NaCl. Homogenates were centrifuged at 1000
g for 10 min and the supernatant was frozen
at -20ºC. The protein contents of the samples
were measured by the method of Bradford
(28) using bovine serum albumin as stand-
ard.
Determination of kinetic parameters for
Abz-peptidyl-K(Dnp)P-OH derivatives
The purified rabbit lung ACE activity on
Abz-FRK(Dnp)P-OH derivatives was deter-
mined at 37ºC in 0.1 M Tris-HCl buffer
containing 50 mM NaCl and 10 µM ZnCl2,
pH 7.0 (1.0 ml final volume). Enzymatic
activity was continuously monitored with a
Hitachi F-2000 (Tokyo, Japan) fluorometer
by measuring fluorescence at λex = 320 nm
and λem = 420 nm. The slope was converted
into µmol substrate hydrolyzed/minute on
the basis of a calibration curve obtained after
complete hydrolysis of each peptide. For the
determination of the kinetic parameters the
enzyme concentration was chosen so as to
hydrolyze less than 5% of the substrate pres-
ent per unit time in order to obtain the initial
rate. To correct for the inner filter effect we
used an adjusting equation determined ex-
perimentally for 0.1 to 100 µM Abz-FR-OH,
used as standard for fluorescence measure-
ments (23). The kcat/Km values were calcu-
lated from the kinetic parameters kcat and Km
obtained by analysis of the non-linear re-
gression data with the GraFit program (29).
The standard deviations of the kcat and Km
values were less than 7%.
Determination of substrate cleavage site
The scissile bonds of the hydrolyzed pep-
tides were determined by isolation of the
fragments by analytical HPLC, and their
structures deduced by amino acid sequenc-
ing using a PPSQ-23 protein sequencer (Shi-
madzu, Tokyo, Japan) and by MALDI-TOF
mass spectrometry.
Determination of ACE activity in human
plasma
Measurement of human plasma ACE ac-
tivity using Hip-His-Leu as substrate was
performed by the fluorometric method de-
scribed by Friedland and Silverstein (15).
Briefly, 10 µl serum was added to the assay
solution containing 5 mM Hip-His-Leu in
0.1 M potassium phosphate buffer, pH 8.3,
containing 0.3 M NaCl, at 37ºC, in a final
volume of 250 µl. The product, His-Leu, was
quantified by measuring the fluorescent ad-
duct formed with ortho-phthaldialdehyde
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with a Hitachi F-2000 spectrofluorometer
(λex = 360 nm and λem = 500 nm). ACE
activity is reported as mU/ml plasma (1 mU
= nmol of histidyl-leucine formed per
minute).
Human plasma ACE activity on Abz-
FRK(Dnp)P-OH was determined under the
optimal experimental conditions (buffer, pH,
chloride and zinc ions) previously estab-
lished for recombinant wild-type ACE (23).
Enzymatic activity was continuously moni-
tored with a Hitachi F-2000 fluorometer by
measuring the fluorescence (λex = 320 nm
and λem = 420 nm) for 5-10 min. Before
starting the reaction by the addition of the
substrate, the plasma was preincubated for 5
min in a thermostated cuvette at 37ºC in the
assay buffer. The sensitivity of the assay was
tested with 1-10 µl plasma incubated in a
final volume of 1 ml. For ACE determina-
tion, 5 µl plasma was incubated with 10 µM
Abz-FRK(Dnp)P-OH at 37ºC in 0.1 M Tris-
HCl, pH 7.0, containing 50 mM NaCl and 10
µM ZnCl2, in a final volume of 1.0 ml. The
slope was converted into nmol substrate hy-
drolyzed per minute based on a calibration
curve obtained by complete hydrolysis of
the peptide as reported previously (23). ACE
activity is reported as mU/ml plasma (1 mU
= nmol of Abz-FRK(Dnp)P-OH hydrolyzed
per minute). The measurements of ACE ac-
tivity in the plasma of 80 healthy subjects
using Hip-His-Leu and Abz-FRK(Dnp)P-
OH as substrates were carried out in dupli-
cate. Data were submitted to regression anal-
ysis and the paired Student t-test was used
for comparison of the means in the correla-
tion study (30).
Determination of ACE activity in rat tissues
ACE activity in rat tissue extracts was
determined using Abz-FRK(Dnp)P-OH de-
rivatives as substrates by continuously meas-
uring the fluorescence in the cuvette (5-10
min) as described above. The assays were
performed at 37ºC in 0.1 M Tris-HCl buffer,
pH 7.0, containing 50 mM NaCl and 10 µM
ZnCl2, in a final volume of 1.0 ml. Inhibitors
of the hydrolytic activities we wanted to
suppress (10 µM E64, 1 µM pepstatin, 1 mM
PMSF, 100 µM TLCK, and 100 µM TPCK)
were added to the buffer. Before starting the
reaction by the addition of 10 µM substrate,
the tissue homogenates (1 to 30 µl) were
preincubated for 5 min in the assay buffer at
37ºC. ACE activity is reported as mU/mg
protein (1 mU = nmol of substrate hydro-
lyzed per minute). The measurements were
performed in duplicate.
Inhibitor studies
ACE activity in the presence of the in-
hibitors was determined using 10 µM Abz-
FRK(Dnp)P-OH as substrate. Lisinopril (0.5
µM) or captopril (0.5 µM) was preincubated
with samples of human plasma or rat tissues
for 30 min at 37ºC before the addition of the
substrate.
Results
Determination of kinetic parameters for
hydrolysis of Abz-peptidyl-K(Dnp)P-OH
analogues by purified rabbit lung ACE
Table 1 shows the kinetic parameters for
hydrolysis by purified rabbit lung ACE of
the peptide Abz-FRK(Dnp)P-OH and its
analogues containing Tyr, Ser and Thr in
place of Phe. The results were similar to
those previously reported for human recom-
binant wild-type ACE (23). The highest kcat/
Km value was observed for Abz-FRK(Dnp)P-
OH, indicating a preference for Phe at the P2
position of the substrates. The four peptides
were cleaved at the Arg-Lys(Dnp) bond, as
determined by HPLC analysis and amino
acid sequencing of the reaction products.
The Pro residue at the C-terminal makes the
substrates more resistant to carboxypepti-
dases. In addition, it is well known from
previous studies with ACE inhibitors that
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Pro in the C-terminal is well accepted by
ACE (31). Abz-FRK(Dnp)P-OH, which was
cleaved with the highest catalytic efficiency
by rabbit lung ACE, was chosen as the refer-
ence substrate.
Measurement of ACE in human plasma
Abz-FRK(Dnp)P-OH was used as sub-
strate to quantify ACE activity in human
plasma. Fluorescence appeared after cleav-
age of the Arg-Lys(Dnp) bond as shown by
HPLC analysis and amino acid sequencing
of the reaction products. The assay required
as little as 1 µl plasma in a final volume of
1 ml. A linear relationship between the rate
of hydrolysis and the volume of human
plasma added was observed in the range
investigated, 1 to 10 µl (Figure 1). Regres-
sion analysis was performed on data for 80
healthy patients using Hip-His-Leu and Abz-
FRK(Dnp)P-OH as substrates, as shown in
Figure 2. The paired Student t-test indicated
that the results obtained correlated and were
significant (r = 0.90, P < 0.001). The hy-
drolysis of Abz-FRK(Dnp)P-OH by human
plasma was completely inhibited by 0.5 µM
lisinopril or captopril, demonstrating the
specificity of the assay.
ACE activity in rat tissues
ACE activities in tissue homogenates of
rat lung, kidney, heart, and liver were exam-
ined using Abz-FRK(Dnp)P-OH as substrate.
In these assays, classical inhibitors of cys-
teine, aspartyl and serine peptidases (10 µM
E64, 1 µM pepstatin, 1 mM PMSF, 100 µM
TLCK, and 100 µM TPCK) were added to
prevent undesirable hydrolysis. Except for
the liver extracts, in which the hydrolysis of
Abz-FRK(Dnp)P-OH was only partially
blocked (58%), in lung, heart and kidney the
cleavage of this substrate was completely
abolished by 0.5 µM lisinopril or captopril
(Table 2). The residual activity in the liver
was inhibited by the addition of 1 mM ortho-
Table 1. Kinetic parameters for the hydrolysis of Abz-FRK(Dnp)P-OH and some of its
derivatives by purified rabbit lung ACE.
Substrate Km (µM) kcat (s-1) kcat/Km (µM-1 s1) Relative kcat/Km
Abz-FRK(Dnp)P-OH 7.9 211.2 45.4 1.0*
Abz-YRK(Dnp)P-OH 7.0 210.0 30.0 0.66
Abz-SRK(Dnp)P-OH 12.6 98.2 7.8 0.17
Abz-TRK(Dnp)P-OH 6.2 16.1 2.6 0.06
Experimental conditions: the assays were performed at 37ºC in 0.1 M Tris-HCl, pH 7.0,
containing 50 mM NaCl and 10 µM ZnCl2, in a final volume of 1.0 ml.
*A relative kcat/Km value of 1.0 was assigned to Abz-FRK(Dnp)P-OH which was
hydrolyzed with the highest catalytic efficiency. Abz-FRK(Dnp)P-OH = ortho-ami-
nobenzoic acid-FRK-(2,4-dinitrophenyl)P-OH.
Figure 1. Linear relation-
ship between the ve-
locity of hydrolysis of 10
µM Abz-FRK(Dnp)P-OH
and the volume of hu-
man plasma. In the in-
set, continuous fluores-
cence recording of the
substrate hydrolysis by
plasma: 1 µl (circles), 2
µl (squares), 5 µl (filled
triangles), 10 µl (filled in-
verted triangles), and 10
µl + 0.5 µM lisinopril (loz-
enges). The slope was
converted into µmol of
substrate hydrolyzed/
min based on a calibra-
tion curve obtained from
complete hydrolysis of Abz-FRK(Dnp)P-OH (slope = 4600 AFU/µM of Abz-FR). Abz-
FRK(Dnp)P-OH = ortho-aminobenzoic acid-FRK-(2,4-dinitrophenyl)P-OH. Measurements
were made in duplicate and differences were <5%.
Figure 2. Linear regres-
sion analysis of paired
data of angiotensin I-con-
verting enzyme activity in
plasma from 80 normal
patients using Hip-His-
Leu (x-axis) and Abz-
FRK(Dnp)P-OH (y-axis)
as substrates. In the
Friedland and Silverstein
method (15), ACE activ-
ity was measured in 10 µl
plasma with 5 mM Hip-
His-Leu as substrate, in
a final volume of 250 µl.
In the method described
here, 5 µl plasma was in-
cubated with 10 µM Abz-
FRK(Dnp)P-OH in a final volume of 1.0 ml. Abz-FRK(Dnp)P-OH = ortho-aminobenzoic
acid-FRK-(2,4-dinitrophenyl)P-OH. The correlation coefficient was r = 0.90, P < 0.001;
paired Student t-test). The assays were performed in duplicate and differences were <10%.
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in the liver and the hydrolysis of Abz-
FRK(Dnp)P-OH by an enzyme different from
ACE, this substrate is not convenient for
ACE determinations in crude extracts of
liver.
Figure 3 shows the sensitivity of Abz-
FRK(Dnp)P-OH for ACE activity detection
at different protein concentrations of rat lung
and kidney. Using this substrate, reliable
ACE activity measurements can be made
with as little as 0.3 µg lung homogenate
while 10 µg kidney homogenate is needed
for the enzyme measurement.
Discussion
ACE measurement in human plasma and
tissues can provide essential information for
the investigation of some physiological and
pathophysiological situations. Colorimetric,
fluorometric and radiolabeled assays have
been described to monitor the enzyme activ-
ity. However, all of these methods have
some limitations. We have previously de-
scribed internally quenched fluorogenic
bradykinin-related peptides bearing a
blocked C-terminal carboxyl group (Abz-
peptidyl-EDDnp) for ACE determination in
purified enzyme preparations and in human
plasma (22). Later, we reported the develop-
ment of highly efficient fluorogenic sub-
strates for the enzyme with the general se-
quence Abz-peptidyl-K(Dnp)P-OH (23). The
activity of recombinant ACEs upon these
peptides with a free C-terminal carboxyl
group was significantly more efficient than
the activity described for Abz-peptidyl-
EDDnp analogues of bradykinin. The ki-
netic parameters for hydrolysis of Abz-
FRK(Dnp)P-OH and Abz-YRK(Dnp)P-OH
by wild-type human recombinant ACE clas-
sify these peptides among the best substrates
described for ACE (23). The improvement
in the sensitivity of the assay and the great
interest in the development of a method for
ACE determinations on a continuous basis
led us to standardize the assay for enzyme
Figure 3. Effect of protein
concentration on the hydro-
lytic activity of rat tissue ho-
mogenates on 10 µM Abz-
FRK(Dnp)P-OH. Initial rates
of hydrolysis were deter-
mined as shown in the in-
sets. A, Lung homogenate
under different concentra-
tions; inset : continuously
fluorescence recording of
the hydrolysis by 0.8 µg
protein in absence (circles),
in presence of the cocktail
of inhibitors (squares) and
in presence of the cocktail
of inhibitors plus 0.5 µM lisi-
nopril (triangles). B, Kidney
homogenate; inset : initial
hydrolysis rate determina-
tion: 30 µg protein in ab-
sence (circles) and in pres-
ence of the cocktail of in-
hibitors (squares) and with





in duplicate and differences
were <5%.
Table 2. Rat tissue ACE activity measurements with Abz-FRK(Dnp)P-OH and inhibi-
tion with 0.5 µM lisinopril or captopril.
Substrate mU per mg of protein (inhibition, %)
Lung Kidney Heart Liver
Abz-FRK(Dnp)P-OH 71.2 (100) 1.1 (100) 0.4 (100) 0.1 (58)
Experimental conditions: the assays were performed at 37ºC in 0.1 M Tris-HCl, pH 7.0,
containing 50 mM NaCl, 10 µM ZnCl2, 10 µM E64, 1 µM pepstatin, 1 mmol/l PMSF, 100
µM TLCK, and 100 µmol/l TPCK, in a final volume of 1.0 ml. Substrate: 10 µM. ACE =
angiotensin converting enzyme; Abz-FRK(Dnp)P-OH = ortho-aminobenzoic acid-FRK-
(2,4-dinitrophenyl)P-OH; PMSF = phenyl-methylsulfonyl fluoride; TPCK = N-tosyl-L-
phenylalanyl-chloromethyl ketone; TLCK = N-tosyl-lysyl-chloromethyl ketone.
phenanthroline, indicating the interference
of a metallopeptidase other than ACE (data
not shown).
The sensitivity of the assay can be evalu-
ated from the data presented in Table 2. As
expected, ACE activity was much higher in
the lung compared to the other tissues. How-
ever, due to the small amount of the enzyme
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activity determinations in human plasma and
crude extracts of rat tissues.
The determination of ACE activity in
clinical studies is normally based on hy-
drolysis of Hip-His-Leu and measurement
of the fluorescence of the ortho-phthaldial-
dehyde-His-Leu adduct (15). This technique
is well established but has the limitation of
being laborious, requiring seven steps. In
addition, depending on the buffer used, the
hydrolysis of His-Leu by dipeptidases pres-
ent in plasma and tissues can underestimate
ACE activity by destroying the compound
that emits the fluorescence (18). The fluoro-
metric method described here has the impor-
tant advantage of being rapid and very sensi-
tive. The assays can be performed directly in
the cuvette of the fluorometer and the hy-
drolysis monitored by continuous recording
for no more than 10 min. Another favorable
point is that the fluorescence signal appears
immediately after hydrolysis, and the fur-
ther hydrolysis of the products resulting from
ACE activity does not interfere with the
fluorescence measurements.
Human plasma ACE concentration is
rather low and in some pathologies the en-
zyme content is decreased. The high cata-
lytic efficiency (52.6 µM-1 s-1) observed for
the hydrolysis of Abz-FRK(Dnp)P-OH by
recombinant human ACE (23) makes this
peptide the most favorable substrate for de-
termination of the enzyme in human plasma.
The regression analysis presented in Figure
2 comparing ACE measurements obtained
with Abz-FRK(Dnp)P-OH to the fluoromet-
ric method which uses Hip-His-Leu as sub-
strate demonstrates that both assays corre-
late closely. For normal subjects, the assay
can be run with 1 µl human plasma in a final
volume of 1 ml. The specificity for ACE
measurements was demonstrated by the com-
plete inhibition of the hydrolytic activity in
the presence of 0.5 µM lisinopril or capto-
pril.
In tissue homogenates, classical inhibi-
tors of serine, aspartyl and cysteine pepti-
dases were used in ACE measurements with
Abz-FRK(Dnp)P-OH to eliminate the inter-
ference of these enzyme classes without af-
fecting ACE activity. However, the interfer-
ence of a metallopeptidase different from
ACE in the liver could not be abolished
(Table 2). Therefore, despite being a very
specific and efficient substrate for ACE de-
terminations in lung, kidney and heart, the
peptide Abz-FRK(Dnp)P-OH was hydro-
lyzed by another peptidase present in the
liver.
A metallopeptidase from human liver
which degrades bradykinin and atrial natri-
uretic peptide was purified to homogeneity
by Carvalho et al. (32). Another possibility
is the interference of the Thimet oligopepti-
dase (EC 3.4.24.15), which has been re-
ported to be the major liver kininase in the
rat (33).
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